CD274 and neoplasm: Although ICIs targeting PD1-PDL1 axis have demonstrated great efficacy among different tumor types and are widely used in daily clinical practice, IDCs targeting PD-L1 are still in an early stage of development, with SGN-PDL1V and HLX43 being the only two tested in humans.